ERBB2 and breast carcinoma: The food and drug administration (FDA) approved scoring system for breast cancer which is entirely based on membranous HER2 overexpression with strict guidelines to ignore cytoplasmic expression as it does not correlate to any clinical outcome (Walker et al., 2008).